MoonLake Immunotherapeutics/$MLTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
100
ISIN
KY61559X1045
Website
MLTX Metrics
BasicAdvanced
$2.8B
-
-$2.30
1.31
-
Price and volume
Market cap
$2.8B
Beta
1.31
52-week high
$58.26
52-week low
$31.42
Average daily volume
574K
Financial strength
Current ratio
21.111
Quick ratio
20.146
Long term debt to equity
17.976
Total debt to equity
18.323
Interest coverage (TTM)
-9,486.45%
Profitability
EBITDA (TTM)
-169.321
Effective tax rate (TTM)
-0.25%
Management effectiveness
Return on assets (TTM)
-19.85%
Return on equity (TTM)
-30.64%
Valuation
Price to book
6.78
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
-19.564
Free cash flow yield (TTM)
-5.11%
Free cash flow per share (TTM)
-222.35%
Growth
Earnings per share change (TTM)
211.65%
Bulls say / Bears say
Merck has engaged in acquisition talks with MoonLake Immunotherapeutics for a potential deal exceeding $3 billion, indicating strong interest in the company's assets. (reuters.com)
Analysts from Needham & Company LLC have initiated coverage on MoonLake with a 'Buy' rating and a price target of $76, citing the company's lead product, sonelokimab, as a potential best-in-class treatment for chronic dermatological ailments. (benzinga.com)
MoonLake's lead product, sonelokimab, has demonstrated remarkable efficacy in treating chronic dermatological conditions, positioning it as a strong competitor in a market estimated at $30 billion. (benzinga.com)
MoonLake Immunotherapeutics reported a quarterly GAAP net loss of $24.27 million for the quarter ending June 30, 2024, indicating ongoing financial challenges. (markets.businessinsider.com)
The company's stock reached a new 52-week low of $36.34 on April 4, 2025, reflecting potential investor concerns about its performance. (techdows.com)
Barclays analyst Leon Wang maintained a 'Hold' rating on MoonLake with a price target of $55, suggesting limited upside potential in the near term. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MLTX News
AllArticlesVideos
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Reuters·3 weeks ago
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewsWire·1 month ago
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $2.8B as of June 20, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of June 20, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.